

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5231361

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	VERTEX PHARMACEUTICALS (EUROPE) LIMITED	09/14/2015
RECEIVING PARTY DATA		
Name:	VERTEX PHARMACEUTICALS INCORPORATED	
Street Address:	50 NORTHERN AVENUE	
City:	BOSTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02210	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16116559
CORRESPONDENCE DATA		
Fax Number:	(617)426-6567	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	6177287100	
Email:	BOSPatents@dechert.com	
Correspondent Name:	DECHERT LLP	
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR	
Address Line 2:	100 OLIVER STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605	
ATTORNEY DOCKET NUMBER:	394927-009USD2 (162816)	
NAME OF SUBMITTER:	ANDREA L.C. REID	
SIGNATURE:	/Andrea L.C. Reid/	
DATE SIGNED:	11/09/2018	
Total Attachments: 3		
source=Merck_Vertex_162816_Parent_Assignment_Vertex_EP_to_Vertex_US#page1.tif		
source=Merck_Vertex_162816_Parent_Assignment_Vertex_EP_to_Vertex_US#page2.tif		
source=Merck_Vertex_162816_Parent_Assignment_Vertex_EP_to_Vertex_US#page3.tif		

ASSIGNMENT

We, Vertex Pharmaceuticals (Europe) Limited, a company registered in England and Wales under registered number 02907620 and having an office and a place of business at 86-88 Jubilee Avenue, Milton Park, Abingdon, Oxfordshire OX14 4RW U.K., for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to, Vertex Pharmaceuticals Incorporated, a corporation organized and existing under the laws of the Commonwealth of Massachusetts and having an office and a place of business at 50 Northern Avenue, Boston, Massachusetts 02210, its successors and assigns, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest in all countries throughout the world in and to any and all of my/our inventions, and discoveries disclosed in:

(a) the application for United States Letters Patent entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, and filed in the United States Patent and Trademark Office on May 28, 2015, under Application Number 14/723,599, including any renewals, revivals, reissues, reexaminations, extensions, continuations, and divisions thereof, and any substitute applications therefor, and/or

(b) the International Patent Application entitled: COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE, filed under the Patent Cooperation Treaty in the United States Receiving Office on May 28, 2015, under Application No. PCT/US15/032879, and designating all countries, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor;

(2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in my/our names at the election of the ASSIGNEE or its designee, on the aforesaid inventions, discoveries and applications in any country throughout the world;

(3) the entire right, title and interest in and to any Letters Patent which may issue thereon in any country throughout the world, and in and to any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof; and

(4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications including, but not limited to, the following priority application(s):

62/008,277	USA	June 5, 2014
Application No.	Country	Filing Date

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by us had this assignment, sale and transfer not been made.

We agree, at any time, upon the request of the ASSIGNEE to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

We further agree at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

By: Kerry A. Flynn
Kerry A. Flynn
Vice President and Chief IP Counsel
on behalf of Vertex Pharmaceuticals (Europe) Limited

Date: September 14, 2015

Commonwealth of Massachusetts
County of Suffolk

On this 14th day of September, 20 15, before me, the undersigned notary public, personally appeared Kerry A. Flynn (name of document signer), proved to me through satisfactory evidence of identification which was/were: ☒ personal knowledge of identity, ☐ a driver's license, ☐ other (please identify) _____, to be the person whose name is signed on this document, and who swore or affirmed to me that the contents of the document are truthful and accurate to the best of his/her knowledge and belief.

Frances M. Cunningham
Notary Public
My Commission Expires: 3/16/2018

